The human telomerase catalytic subunit human telomerase reverse transcriptase (hTERT) is expressed in many human cancer cells derived from multiple tissues, but infrequently in normal cells. Thus, hTERT is an attractive candidate target for tumor immunotherapy. hTERT:540–548 peptide (p540, ILAKFLHWL) has been identified as an effective HLA-A*0201-restricted T-cell epitope, an effective T-cell-based cancer treatment, including vaccines, against hTERT will likely require the identification of other MHC class I-restricted epitopes in this antigen.

> 95% as determined by Bis-Tris PAGE; > 95% as determined by HPLC